Systemic Embolism
DOACs lower stroke, raise hemorrhage risk in those with prior brain hemorrhage plus AF
The benefit of direct oral anticoagulants on stroke risk in patients with prior intracerebral hemorrhage and atrial fibrillation was partially offset by increased risk for future hemorrhage risk, a speaker reported.
Mass ECG screening for atrial fibrillation in older adults does not seem to prevent stroke
Mass ECG screening for atrial fibrillation in older adults did not reduce the incidence of stroke or stroke hospitalization, according to the results of two trials presented at the European Society of Cardiology Congress.
Asundexian did not prevent stroke, systemic embolism vs. apixaban in atrial fibrillation
Treatment of atrial fibrillation with asundexian, a novel factor XIa inhibitor, was associated with increased stroke and systemic embolism risk despite lower bleeding risk compared with apixaban, a speaker reported.
Apixaban, aspirin comparable for patients with cancer history, cryptogenic stroke
Apixaban and aspirin offered similar protection against major ischemic and hemorrhagic events among people with cancer history and cryptogenic stroke.
In patients with subclinical AF, apixaban reduces stroke risk, raises bleeding risk
PHILADELPHIA — In patients with subclinical atrial fibrillation, apixaban lowered risk for stroke but increased risk for bleeding compared with aspirin, according to the results of the ARTESIA trial.
Asundexian gains fast track designation for stroke prevention in patients with AF
Bayer announced the FDA has granted fast track designation for asundexian — a once-daily oral factor XIa inhibitor — for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Continuous AF monitoring does not reduce risk for stroke, systemic embolism: LOOP
Continuous implantable loop recorder monitoring resulted in a threefold increase in atrial fibrillation detection and subsequent anticoagulation initiation, but failed to reduce risk for stroke or systemic embolism in high-risk patients.
ELDERCARE-AF
Low-dose edoxaban (Savaysa, Daiichi Sankyo) vs. placebo for prevention of stroke and systemic embolism in patients aged at least 80 years with AF.
Low-dose edoxaban prevents thrombotic events without major bleeding risk in very elderly
In adults aged 80 years and older with atrial fibrillation, once-daily, low-dose edoxaban was superior to placebo for preventing stroke or systemic embolism and did not significantly increase major bleeding in the ELDERCARE-AF trial.
LAA closure noninferior to direct oral anticoagulants in high-risk AF
Among patients with atrial fibrillation at high risk for stroke, left atrial appendage closure was noninferior compared with direct oral anticoagulants, researchers reported in the randomized PRAGUE-17 trial.